These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 34789492)

  • 1. Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA.
    Smeltzer MP; Howell KE; Treadwell M; Preiss L; King AA; Glassberg JA; Tanabe P; Badawy SM; DiMartino L; Gibson R; Kanter J; Klesges LM; Hankins JS;
    BMJ Open; 2021 Nov; 11(11):e050880. PubMed ID: 34789492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers and facilitators to care for individuals with sickle cell disease in central North Carolina: The emergency department providers' perspective.
    Masese RV; Bulgin D; Douglas C; Shah N; Tanabe P
    PLoS One; 2019; 14(5):e0216414. PubMed ID: 31063506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department.
    Linton EA; Goodin DA; Hankins JS; Kanter J; Preiss L; Simon J; Souffront K; Tanabe P; Gibson R; Hsu LL; King A; Richardsona LD; Glassberg JA;
    Ann Emerg Med; 2020 Sep; 76(3S):S64-S72. PubMed ID: 32928465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study.
    Hankins JS; Shah N; DiMartino L; Brambilla D; Fernandez ME; Gibson RW; Gordeuk VR; Lottenberg R; Kutlar A; Melvin C; Simon J; Wun T; Treadwell M; Calhoun C; Baumann A; Potter MB; Klesges L; Bosworth H;
    JMIR Res Protoc; 2020 Jul; 9(7):e16319. PubMed ID: 32442144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Care Providers' Comfort Levels in Caring for Patients with Sickle Cell Disease.
    Whiteman LN; Haywood C; Lanzkron S; Strouse JJ; Feldman L; Stewart RW
    South Med J; 2015 Sep; 108(9):531-6. PubMed ID: 26332477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.
    Lanzkron S; Haywood C; Hassell KL; Rand C
    J Natl Med Assoc; 2008 Aug; 100(8):968-73. PubMed ID: 18717150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Needs Assessment of Persons With Sickle Cell Disease in a Major Medical Center in North Carolina.
    Masese RV; Crego N; Douglas C; Rains G; Bonnabeau E; DeMartino T; Shah N; Tanabe P
    N C Med J; 2021; 82(5):312-320. PubMed ID: 34544765
    [No Abstract]   [Full Text] [Related]  

  • 8. An Integrative Review: The Evolution of Provider Knowledge, Attitudes, Perceptions and Perceived Barriers to Caring for Patients with Sickle Cell Disease 1970-Now.
    Reich J; Cantrell MA; Smeltzer SC
    J Pediatr Hematol Oncol Nurs; 2023; 40(1):43-64. PubMed ID: 35854420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating sickle cell guidelines into practice for primary care providers with Project ECHO.
    Shook LM; Farrell CB; Kalinyak KA; Nelson SC; Hardesty BM; Rampersad AG; Saving KL; Whitten-Shurney WJ; Panepinto JA; Ware RE; Crosby LE
    Med Educ Online; 2016; 21():33616. PubMed ID: 27887664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What does it mean to be affiliated with care?: Delphi consensus on the definition of "unaffiliation" and "specialist" in sickle cell disease.
    Lamont AE; Hsu LL; Jacobs S; Gibson R; Treadwell M; Chen Y; Lottenberg R; Axelrod K; Varughese T; Melvin C; Smith S; Chukwudozie IB; Kanter J;
    PLoS One; 2022; 17(11):e0272204. PubMed ID: 36367870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric hematology providers' contraceptive practices for female adolescents and young adults with sickle cell disease: A national survey.
    Askew MA; Smaldone AM; Gold MA; Smith-Whitley K; Strouse JJ; Jin Z; Green NS
    Pediatr Blood Cancer; 2022 Oct; 69(10):e29877. PubMed ID: 35856776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
    Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
    JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in Jos, North-Central Nigeria.
    Ofakunrin AO; Okpe ES; Afolaranmi TO; Olaosebikan RR; Kanhu PU; Adekola K; Dami N; Sagay AS
    Afr Health Sci; 2021 Jun; 21(2):765-774. PubMed ID: 34795734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to Hydroxyurea and Patients' Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study.
    Madkhali MA; Abusageah F; Hakami F; Zogel B; Hakami KM; Alfaifi S; Alhazmi E; Zaalah S; Trabi S; Alhazmi AH; Mohrag M; Malhan H
    Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256385
    [No Abstract]   [Full Text] [Related]  

  • 16. Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability.
    Ryan N; Dike L; Ojo T; Vieira D; Nnodu O; Gyamfi J; Peprah E
    BMJ Open; 2020 Nov; 10(11):e038685. PubMed ID: 33168553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017.
    Su ZT; Segal JB; Lanzkron S; Ogunsile FJ
    Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1246-1250. PubMed ID: 31328369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergency Department Provider Survey Regarding Acute Sickle Cell Pain Management.
    Martin OY; Thompson SM; Carroll AE; Jacob SA
    J Pediatr Hematol Oncol; 2020 Aug; 42(6):375-380. PubMed ID: 32569034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes of Primary Care Physicians Toward Sickle Cell Disease Care, Guidelines, and Comanaging Hydroxyurea With a Specialist.
    Lunyera J; Jonassaint C; Jonassaint J; Shah N
    J Prim Care Community Health; 2017 Jan; 8(1):37-40. PubMed ID: 27506442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
    Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
    Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.